glp-1 agonist therapy glp-1_analogs [TUSOM GLP-1 Personalized Treatment for Weight

Liraglutide, a glucagon-like peptide-1 receptor agonist, ameliorates inflammation and apoptosis via inhibition of receptor for advanced glycation end products signaling in AGEs induced chondrocytes

So, while DPP-IVs may offer a better gastrointestinal (GI) adverse event profile than GLP-1RAs, they are generally less effective at reducing HbA 1C and have a lower potential for weight loss

None of the AEs led to premature treatment discontinuation

117 Interestingly, glucagon also exerts insulinotropic effects on islet beta-cells, and this is likely to allow for tissues to uptake glucose and fat once glucagon has induced their catabolism from nutrient storage (as tissues such as skeletal muscle rely on insulin for nutrient uptake from circulation), or the insulinotropic effects of glucagon could simply serve as a feedback inhibition mechanism

More specifically, Bhagavathula and colleagues pooled efficacy outcome data in the same analysis irrespective of type of comparator (placebo or GLP-1 RA) [26]